CN1239159C - 降血脂药物组合物 - Google Patents
降血脂药物组合物 Download PDFInfo
- Publication number
- CN1239159C CN1239159C CN 02112488 CN02112488A CN1239159C CN 1239159 C CN1239159 C CN 1239159C CN 02112488 CN02112488 CN 02112488 CN 02112488 A CN02112488 A CN 02112488A CN 1239159 C CN1239159 C CN 1239159C
- Authority
- CN
- China
- Prior art keywords
- group
- pharmaceutical composition
- salviae miltiorrhizae
- radix salviae
- fructus crataegi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 229940079593 drug Drugs 0.000 title abstract description 16
- 210000004369 blood Anatomy 0.000 title description 18
- 239000008280 blood Substances 0.000 title description 18
- 239000000203 mixture Substances 0.000 title description 15
- 230000001603 reducing effect Effects 0.000 title description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 56
- 239000002253 acid Substances 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 28
- 150000007965 phenolic acids Chemical class 0.000 claims abstract description 24
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 35
- 150000003648 triterpenes Chemical class 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 235000009048 phenolic acids Nutrition 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- 230000002402 anti-lipaemic effect Effects 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 13
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract description 10
- 240000007164 Salvia officinalis Species 0.000 abstract description 5
- 235000005412 red sage Nutrition 0.000 abstract description 2
- 239000002775 capsule Substances 0.000 description 39
- 210000002966 serum Anatomy 0.000 description 26
- 210000004185 liver Anatomy 0.000 description 25
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 25
- 108010023302 HDL Cholesterol Proteins 0.000 description 24
- 108010028554 LDL Cholesterol Proteins 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 23
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 19
- 150000002632 lipids Chemical class 0.000 description 18
- 235000005687 corn oil Nutrition 0.000 description 13
- 101150102415 Apob gene Proteins 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000037396 body weight Effects 0.000 description 11
- 239000008802 xuezhikang Substances 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 241000283977 Oryctolagus Species 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 8
- 238000003304 gavage Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000011777 magnesium Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000018616 Apolipoproteins B Human genes 0.000 description 3
- 108010027006 Apolipoproteins B Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 235000017276 Salvia Nutrition 0.000 description 3
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 description 3
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000282894 Sus scrofa domesticus Species 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229930183842 salvianolic acid Natural products 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940096998 ursolic acid Drugs 0.000 description 3
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 3
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 2
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000019637 Infantile Diarrhea Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 2
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229960003371 protocatechualdehyde Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 244000132619 red sage Species 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000004879 turbidimetry Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 235000017159 Crataegus pinnatifida Nutrition 0.000 description 1
- 241000657480 Crataegus pinnatifida Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000237903 Hirudo Species 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020590 Hypercalciuria Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- HWGBHCRJGXAGEU-UHFFFAOYSA-N Methylthiouracil Chemical compound CC1=CC(=O)NC(=S)N1 HWGBHCRJGXAGEU-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- 101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FHNINJWBTRXEBC-UHFFFAOYSA-N Sudan III Chemical compound OC1=CC=C2C=CC=CC2=C1N=NC(C=C1)=CC=C1N=NC1=CC=CC=C1 FHNINJWBTRXEBC-UHFFFAOYSA-N 0.000 description 1
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
- KNDHRUPPBXRELB-UHFFFAOYSA-M [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride Chemical compound [Cl-].C1=CC(CC)=CC=C1C(C)CCC1=CC=C([N+](C)(C)C)C=C1 KNDHRUPPBXRELB-UHFFFAOYSA-M 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001678 colestyramine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 125000000567 diterpene group Chemical group 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940043316 hawthorn preparation Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002879 macerating effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960002545 methylthiouracil Drugs 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
组别(n=10) | TC(mmol/L) | TG(mmol/L) | HDL-C(mmol/L) | LDL-C(mmol/L) | 肝重量系数(g肝重/100g体重) |
正常对照组高脂模型组小剂量组(40mg/kg)中剂量组(80mg/kg)大剂量组(160mg/kg)血脂康组(100mg/kg) | 1.701±0.260**3.595±0.7423.456±0.8163.473±0.8592.996±0.478*3.429±0.647 | 0.245±0.093**0.660±0.2530.499±0.1700.362±0.112**0.366±0.172**0.353±0.129** | 1.07±0.187**0.546±0.1080.639±0.1590.69±0.143*0.63±0.063*0.634±0.152 | 0.526±0.144**2.749±0.8042.590±0.8142.475±1.0482.192±0.5072.635±0.629 | 3.183±0.203*3.828±0.2693.791±0.2143.741±0.2073.671±0.2263.531±0.258 |
组别(n=8) | 给药天数(d) | TC(mmol/L) | TG(mmol/L) | HDL-C(mmol/L) | LDL-C(mmol/L) | apoA1(g/L) | ApoB(g/L) |
正常对照组高脂模型组 | 正常饲料7正常饲料17正常饲料31正常饲料7高脂饲料14高脂饲料28 | 1.143±0.2911.004±0.296**1.131±0.377**1.140±0.2182.815±0.8745.640±1.598 | 0.513±0.1580.529±0.2250.581±0.275**0.533±0.1601.210±0.8891.653±0.693 | 0.431±0.0880.399±0.1670.321±0.169**0.427±0.0890.504±0.1770.538±0.205 | 0.478±0.2770.365±0.212*0.545±0.260**0.471±0.2251.562±1.1764.288±1.549 | 0.366±0.0510.140±0.066*0.140±0.0330.391±0.0520.211±0.0530.186±0.055 | 0.132±0.0290.162±0.024*0.098±0.024**0.134±0.0250.240±0.0750.153±0.028 |
胶囊小剂量组(25mg/kg)胶囊中剂量组(50mg/kg)胶囊大剂量组(100mg/kg)血脂康组(65mg/kg) | 正常饲料7给药17给药31正常饲料7给药17给药31正常饲料7给药17给药31正常饲料7给药17给药31 | 1.075±0.2362.456±1.4661.906±0.938**1.159±0.2702.461±1.2691.546±0.499**1.162±0.2421.854±0.618*1.316±0.337**1.083±0.2121.894±0.9531.633±0.608* | 0.499±0.0440.904±0.3661.372±0.7630.522±0.1770.907±0.4111.189±0.5830.518±0.1980.660±0.2520.933±0.436*0.533±0.1490.462±0.269*0.742±0.388* | 0.382±0.1070.550±0.1830.261±0.087**0.401±0.0800.507±0.1420.291±0.138**0.396±0.0750.467±0.1790.307±0.112**0.425±0.0890.482±0.1570.367±0.179* | 0.466±0.1431.494±1.2731.026±0.792**0.521±0.2571.542±1.1410.715±0.583**0.531±0.2511.087±0.5650.589±0.274**0.416±0.1781.182±0.9050.929±0.611** | 0.385±0.0440.237±0.1150.158±0.0480.376±0.0490.291±0.1350.169±0.0610.363±0.0490.311±0.103*0.181±0.0690.378±0.0480.264±0.0610.163±0.033 | 0.143±0.0220.150±0.0450.130±0.0260.128±0.0210.131±0.049**0.143±0.0530.137±0.0180.100±0.015**0.104±0.020**0.135±0.0220.099±0.019**0.116±0.025* |
组别(n=8) | 肝脂质(mg/g湿组织) | 肝重量系数(g肝重/100g体重) | |
TC | TG | ||
正常对照组高脂模型组胶囊25mg/kg组胶囊50mg/kg组胶囊100mg/kg组血脂康65mg/kg组 | 1.94±0.50**3.41±1.132.04±0.40**1.88±0.40**1.88±0.52**1.90±0.36** | 5.77±0.97*7.55±1.386.44±2.046.69±1.415.56±0.77**6.01±0.88** | 3.372±0.597*4.138±0.6953.625±0.9933.543±1.1743.208±0.423**3.313±0.467* |
组别(n=8) | 给药天数(d) | TC(mmol/L) | TG(mmol/L) | HDL-C(mmol/L) | LDL-C(mmol/L) | apoA1(g/L) | ApoB(g/L) |
正常对照组 | 正常饲料7正常饲料14正常饲料42 | 1.018±0.2081.241±0.349**1.793±0.323** | 0.669±0.1780.64±0.139*0.944±0.402* | 0.428±0.1400.24±0.076**0.30±0.088** | 0.285±0.0870.70±0.351**1.03±0.277** | 0.159±0.0290.18±0.045*0.219±0..030 | 0.194±0.0720.184±0.1220.114±0.056* |
高脂模型组 | 正常饲料56正常饲料7脂肪乳剂14脂肪乳剂42脂肪乳剂减半14 | 1.090±0.257**0.922±0.3274.265±2.2769.090±2.6704.320±2.112 | 0./84±0.402*0.719±0.1721.065±04751.327±0.8751.549±0.641 | 0.26±0.094*0.360±0.1320.533±0.0150.818±0.4040.775±0.631 | 0.43±0.306**0.235±0.1353.248±0.1307.669±2.5622.842±1.682 | 0.22±0.033**0.169±0.0220.261±0.0710.245±0.0820.127±0.018 | 0.166±0.0380.154±0.0290.289±0.1240.230±0.1320.196±0.029 |
胶囊小剂量组(25mg/kg) | 正常饲料7脂肪乳剂14给药28给药42 | 0.874±0.2674.407±1.8685.873±4.1952.222±1.175* | 0.880±0.4141..379±0.6881.033±0.3451.197±0.338 | 0.326±0.1030.0557±0.2710.605±0.2500.512±0.221 | 0.182±0.1683.224±1.7384.799±3.9661.16±1.014* | 0.182±0.0250.270±0.0770.239±0.0480.17±0.018** | 0.164±0.0460.286±0.1700.197±0.1180.176±0.031 |
胶囊中剂量组(50mg/kg) | 正常饲料7脂肪乳剂14给药28给药42 | 0.984±0.2424.751±1.7764.428±2.749**1.513±0.539** | 0.787±0.2561.386±0.6241.356±0.3970.99±0.361 | 0.416±0.0930.535±0.1930.551±0.1680.407±0.167 | 0.210±0.1443.586±1.4963.26±2.756**0.65±0.462** | 0.172±0.0420.280±0.0680.224±0.0300.19±0.017** | 0.176±0.0300.386±0.1810.170±0.0850.15±0.035** |
胶囊大剂量组(100mg/kg) | 正常饲料7脂肪乳剂14给药28给药42 | 0.960±0.1404.731±2.8044.431±2.068**1.415±0.508** | 0.869±0.4141.130±0.3251.377±0.5070.94±0.420 | 0.445±0.1230.450±0.1960.528±0..2010.370±0.108 | 0.183±0.1433.376±2.6833.27±1.830**0.61±0.354** | 0.176±0.0250.37±0.051**0.235±0.0300.24±0.027** | 0.177±0.0230.270±0.1240.112±0.042*0.14±0.049* |
血脂康组(65mg/kg) | 正常饲料7脂肪乳剂14给药28给药42 | 0.969±0.3514.257±2.3815.696±2.464*1.849±0.868** | 0.708±0.3191.224±0.3191.585±0.6551.176±0.496 | 0.353±0.0160.531±0.2130.587±0.1780.410±0.180 | 0.299±0.2503.170±2.2594.38±2.461**0.90±0.681** | 0.163±0.0230.36±0.0730.216±0.0480.21±0.030** | 0.166±0.0370.334±0.2430.117±0.035*0.152±0.059 |
组别(n=8) | 肝脂质(mg/g湿组织) | 肝重量系数(g肝重/100g体重) | |
TC | TG | ||
正常对照组高脂模型组胶囊25mg/kg组胶囊50mg/kg组胶囊100mg/kg组血脂康65mg/kg | 2.28±0.42**4.60±1.412.79±1.04*2.71±0.90**2.60±0.46**2.57±0.76** | 9.77±0.67**14.18±3.0011.11±2.15*10.61±0.769.55±1.41**9.88±1.75** | 2.485±0.238**3.463±0.2072.778±0.448**2.649±0.305**2.606±0.353**2.839±0.573* |
组别(n=8) | TC(mmol/L) | TG(mmol/L) | HDL-C(mmol/L) | LDL-C(mmol/L) | apoA1(g/L) | ApoB(g/L) |
正常对照组高脂模型组胶囊小剂量组胶囊中剂量组( | 7.274±1.084**51.70±15.55530.9±13.655**34.06±13.282* | 1.39±0.716**3.246±0.7101.77±0.893**2.32±1.049* | 4.349±0.5504.402±0.9674.017±0.7314.440±1.126 | 2.29±1.418**45.8±15.78926±13.207**28±13.421* | 0.07±0.026**1.421±0.3261.584±0.3051.791±0.454 | 0.095±0.029**2.811±1.2232.173±1.0082.255±1.056 |
胶囊大剂量组血脂康对照组 | 37.40±15.92328±12.346** | 2.503±1.3151.7±0.80** | 3.907±1.0694.4±0.850 | 32.3±16.1142.0±11.855** | 1.745±0.6601.590±0.33 | 1.919±1.0692.479±0.794 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02112488 CN1239159C (zh) | 2002-07-12 | 2002-07-12 | 降血脂药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02112488 CN1239159C (zh) | 2002-07-12 | 2002-07-12 | 降血脂药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1466949A CN1466949A (zh) | 2004-01-14 |
CN1239159C true CN1239159C (zh) | 2006-02-01 |
Family
ID=34141948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02112488 Expired - Lifetime CN1239159C (zh) | 2002-07-12 | 2002-07-12 | 降血脂药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1239159C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106377574B (zh) * | 2016-06-14 | 2019-11-01 | 张均田 | 一种降血脂的药物组合物及其制备方法与用途 |
-
2002
- 2002-07-12 CN CN 02112488 patent/CN1239159C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1466949A (zh) | 2004-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102233119A (zh) | 一种治疗脂肪肝的中药组合物及其制备方法 | |
CN1299742C (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN1069542C (zh) | 一种治疗慢性肝病的药物及其制备方法 | |
CN101053580A (zh) | 中药女贞子的新医药用途及其提取物的制备方法 | |
CN1558768A (zh) | 一种中药组合物及其制备方法 | |
CN102319289A (zh) | 肉桂多酚等组成的降血糖中药组合物及其制备方法 | |
CN100355448C (zh) | 一种防治酒精性肠道损伤和肝损伤的中药复方制剂 | |
CN1239159C (zh) | 降血脂药物组合物 | |
CN101041037A (zh) | 一种治疗糖尿病肾病的药物组合及其制备方法 | |
CN109662967A (zh) | 一种抗抑郁药物及其用途 | |
CN1264533C (zh) | 一种复方丹参胶囊及制备方法 | |
CN101116661A (zh) | 5-羟甲基糠醛在制备保护血管内皮细胞药物中的应用 | |
CN1709415A (zh) | 石刁柏提取物及其制备方法 | |
CN108404088B (zh) | 一种治疗ⅱ型糖尿病的中药及其制备方法 | |
CN101040905B (zh) | 用夏枯草制备的降血糖药物 | |
CN1216613C (zh) | 一种具有调节血脂作用的保健品及制备方法 | |
US11957726B2 (en) | Pharmaceutical composition for controlling blood sugar | |
CN101966239B (zh) | 一种用于预防和治疗心脑血管疾病的中药组合物及其制备方法 | |
CN1209141C (zh) | 一种减肥降脂中药胶囊制剂 | |
CN1839869A (zh) | 莫罗苷在α-葡萄糖苷酶抑制剂中的应用 | |
CN101322825A (zh) | 一种治疗恶性肿瘤的药物组合物 | |
CN109966283A (zh) | 脱脂肉桂多酚提取物在制备防治糖尿病肾病产品中的应用 | |
CN105343206B (zh) | 一种降血压、血脂的复配中药提取物及其制备方法 | |
CN1672719A (zh) | 首乌在制备治疗脂肪肝病药物中的应用 | |
CN110403981A (zh) | 一种中药萃取物在制备治疗脂肪肝的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HAITIAN MEDICINE SCIENCE AND TECHNOLOGY DEVELOPME Effective date: 20050204 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050204 Address after: 215007 No. 48 Renmin Road, Jiangsu, Suzhou Applicant after: Suzhou Institute of Traditional Chinese Medicine Co-applicant after: Shanghai Haitian Medical Technology Development Co.,Ltd. Address before: 215007 No. 48 Renmin Road, Jiangsu, Suzhou Applicant before: Suzhou Institute of Traditional Chinese Medicine |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CX01 | Expiry of patent term |
Granted publication date: 20060201 |
|
CX01 | Expiry of patent term | ||
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Han Rong Document name: Notice of Patent Expiration and Termination |